Condition: Endometrial Cancer · Cervical Cancer · Ovarian Cancer · Sponsor: SystImmune Inc.
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
This description comes directly from the study's public registry record.
Christine LaRock · 425-453-6841 · christine.larock@systimmune.com
Whitney Eakins · 425-453-6841 · whitney.eakins@systimmune.com
Always discuss trial participation with your own doctor first.
| University of Alabama Birmingham | Birmingham, Alabama, United States | Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| Cedars Sinai | Los Angeles, California, United States | Recruiting |
| Scripps Health | San Diego, California, United States | Not Yet Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Sarah Cannon Research institute - Lake Nona Florida | Orlando, Florida, United States | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta, Georgia, United States | Recruiting |
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Chicago Medicine | Chicago, Illinois, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Karmanos Cancer Institiute | Detroit, Michigan, United States | Recruiting |
| NYU Langone Hospital - Long Island Investigational Pharmacy | Mineola, New York, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06293898